Related Experiment Videos
[Alpha-2 macroglobulin from cerebrospinal fluid in neurosurgical diseases]
Abstract:
Content of alpha 2-macroglobulin (alpha 2-MG) was estimated in cerebrospinal fluid (CSF) of patients with neurosurgical impairments. Minimal content of the globulin was found in patients with brain concussion (0.011 +/- 0.001 g/L, control group), maximal concentration--in severe craniocerebral trauma with brain contraction (0.056 +/- 0.007 g/L) and moderately increased content of alpha 2-MG was detected in intracranial tumors and drug-resistant epilepsy, 0.028 +/- 0.004 g/L and 0.025 +/- 0.004 g/L, respectively. Alteration in content of alpha 2-MG during postoperational period corresponded to clinical state of patients. Estimation of alpha 2-MG in CSF might be used as a criterion of brain impairment severity as well as for monitoring the treatment course.
Insights
Alpha 2-macroglobulin (alpha 2-MG) levels in cerebrospinal fluid (CSF) indicate brain injury severity. Monitoring alpha 2-MG in CSF can track patient recovery after neurosurgery.
Area of Science:
- Biochemistry
- Neurology
- Neurosurgery
Context:
- Alpha 2-macroglobulin (alpha 2-MG) is a proteinase inhibitor found in cerebrospinal fluid (CSF).
- Neurosurgical impairments, including brain concussion, severe craniocerebral trauma, intracranial tumors, and drug-resistant epilepsy, can affect protein levels in CSF.
- Previous research has not fully elucidated the role of alpha 2-MG in various neurosurgical conditions.
Purpose:
- To quantify alpha 2-macroglobulin (alpha 2-MG) levels in the cerebrospinal fluid (CSF) of patients with diverse neurosurgical impairments.
- To correlate alpha 2-MG concentrations with the severity of brain injury and specific neurological conditions.
- To evaluate the potential of alpha 2-MG as a biomarker for monitoring treatment efficacy and clinical status post-neurosurgery.
Summary:
- Alpha 2-macroglobulin (alpha 2-MG) levels were measured in the CSF of patients with neurosurgical conditions.
- CSF alpha 2-MG was lowest in brain concussion (0.011 g/L) and highest in severe craniocerebral trauma (0.056 g/L).
- Moderately elevated levels were observed in intracranial tumors (0.028 g/L) and drug-resistant epilepsy (0.025 g/L), correlating with clinical status.
Impact:
- CSF alpha 2-MG levels serve as a potential biomarker for assessing the severity of brain impairment.
- Monitoring alpha 2-MG in CSF can aid in tracking the course of treatment and patient recovery in neurosurgical cases.
- This research may lead to improved diagnostic and prognostic tools for neurological disorders.